MX2021003901A - Derivados de 5-azaindazol como antagonistas del receptor de adenosina. - Google Patents

Derivados de 5-azaindazol como antagonistas del receptor de adenosina.

Info

Publication number
MX2021003901A
MX2021003901A MX2021003901A MX2021003901A MX2021003901A MX 2021003901 A MX2021003901 A MX 2021003901A MX 2021003901 A MX2021003901 A MX 2021003901A MX 2021003901 A MX2021003901 A MX 2021003901A MX 2021003901 A MX2021003901 A MX 2021003901A
Authority
MX
Mexico
Prior art keywords
receptor antagonists
adenosine receptor
azaindazole derivatives
azaindazole
derivatives
Prior art date
Application number
MX2021003901A
Other languages
English (en)
Inventor
Thomas Catelain
Stanislas Mayer
Stephan Schann
Ismet Dorange
Baptiste Manteau
Anne- Laure BLAYO
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of MX2021003901A publication Critical patent/MX2021003901A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

La presente invención se relaciona con nuevos derivados de 5-azaindazol de la fórmula (I), como se describe y define en la presente, y sus sales, solvatos y profármacos farmacéuticamente aceptables, así como composiciones farmacéuticas que comprenden tales compuestos. Se ha descubierto que los derivados de 5-azaindazol de acuerdo con la invención son antagonistas del receptor de adenosina duales A2A/A2B altamente eficaces y, por lo tanto, pueden usarse como agentes terapéuticos, particularmente en el tratamiento o prevención de enfermedades o trastornos hiperproliferativos o infecciosos.
MX2021003901A 2018-10-25 2019-10-22 Derivados de 5-azaindazol como antagonistas del receptor de adenosina. MX2021003901A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18306389 2018-10-25
PCT/EP2019/078665 WO2020083878A1 (en) 2018-10-25 2019-10-22 5-azaindazole derivatives as adenosine receptor antagonists

Publications (1)

Publication Number Publication Date
MX2021003901A true MX2021003901A (es) 2021-06-04

Family

ID=64267732

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021003901A MX2021003901A (es) 2018-10-25 2019-10-22 Derivados de 5-azaindazol como antagonistas del receptor de adenosina.

Country Status (14)

Country Link
US (1) US20210380606A1 (es)
EP (1) EP3870582B1 (es)
KR (1) KR20210083287A (es)
CN (1) CN112867715B (es)
AU (1) AU2019363662A1 (es)
BR (1) BR112021007435A2 (es)
CA (1) CA3117510A1 (es)
DK (1) DK3870582T3 (es)
ES (1) ES2960883T3 (es)
IL (1) IL282526A (es)
MX (1) MX2021003901A (es)
SG (1) SG11202104078PA (es)
TW (1) TW202112772A (es)
WO (1) WO2020083878A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4255904A2 (en) * 2020-12-03 2023-10-11 Domain Therapeutics Novel par-2 inhibitors
WO2022258622A1 (en) 2021-06-07 2022-12-15 Ares Trading S.A. Combination treatment of cancer

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4207554A (en) 1972-08-04 1980-06-10 Med-El Inc. Method and apparatus for automated classification and analysis of cells
US4125828A (en) 1972-08-04 1978-11-14 Med-El Inc. Method and apparatus for automated classification and analysis of cells
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
US6184225B1 (en) 1996-02-13 2001-02-06 Zeneca Limited Quinazoline derivatives as VEGF inhibitors
DE69709319T2 (de) 1996-03-05 2002-08-14 Astrazeneca Ab 4-anilinochinazolin derivate
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
AU1688599A (en) 1998-01-05 1999-07-26 Eisai Co. Ltd. Purine derivatives and adenosine a2 receptor antagonists serving as preventives/remedies for diabetes
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
EP1221444B1 (en) 1999-07-02 2005-08-31 Eisai Co., Ltd. Fused imidazole compounds and remedies for diabetes mellitus
JP2003535078A (ja) 2000-05-31 2003-11-25 アストラゼネカ アクチボラグ 血管損傷活性のあるインドール誘導体
BR0112224A (pt) 2000-07-07 2003-06-10 Angiogene Pharm Ltd Composto, composição farmacêutica, uso de um composto ou de um sal, solvato ou pró-droga farmaceuticamente aceitável do mesmo, e, processo para preparar um composto
EP1301498A1 (en) 2000-07-07 2003-04-16 Angiogene Pharmaceuticals Limited Colchinol derivatives as angiogenesis inhibitors
WO2004089942A2 (en) 2001-10-02 2004-10-21 Acadia Pharmaceuticals Inc. Benzimidazolidinone derivatives as muscarinic agents
AU2002356962C1 (en) 2001-12-12 2008-05-01 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Methods for using extracellular adenosine inhibitors and adenosine receptor inhibitors to enhance immune response and inflammation
EP1618108A2 (en) 2003-04-09 2006-01-25 Biogen Idec MA Inc. Triazolo[1,5-a]pyrimidines and pyrazolo[1,5-a]pyrimidines useful as a2a adenosine receptor antagonists
RU2351597C2 (ru) 2003-05-19 2009-04-10 Ф.Хоффманн-Ля Рош Аг Производные бензотиазола в качестве лигандов аденозиновых рецепторов
AU2004274154A1 (en) 2003-09-19 2005-03-31 F. Hoffmann-La Roche Ag Thiazolopyridine derivatives as adenosine receptor ligands
RU2382782C2 (ru) 2004-07-22 2010-02-27 Ф. Хоффманн-Ля Рош Аг Производные бензотиазола
WO2008112695A2 (en) 2007-03-12 2008-09-18 Irm Llc Pyrazolo [3,4-d] pyrimidines and 1, 2, 5, 6-tetraaza- as- indacenes as protein kinase inhibitors for cancer treatment
EP2210891A1 (en) 2009-01-26 2010-07-28 Domain Therapeutics New adenosine receptor ligands and uses thereof
US9233979B2 (en) 2012-09-28 2016-01-12 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
AR101198A1 (es) * 2014-07-16 2016-11-30 Gruenenthal Gmbh Pirimidinas 2,5-sustituidas como inhibidores de pde4b
CN108368057B (zh) 2015-08-20 2022-03-15 捷思英达医药技术（上海）有限公司 作为erk抑制剂的吡唑并稠合的杂环化合物

Also Published As

Publication number Publication date
JP2022505978A (ja) 2022-01-14
US20210380606A1 (en) 2021-12-09
CA3117510A1 (en) 2020-04-30
TW202112772A (zh) 2021-04-01
EP3870582A1 (en) 2021-09-01
SG11202104078PA (en) 2021-05-28
BR112021007435A2 (pt) 2021-08-03
WO2020083878A1 (en) 2020-04-30
ES2960883T3 (es) 2024-03-07
CN112867715B (zh) 2024-03-05
DK3870582T3 (da) 2023-10-16
EP3870582B1 (en) 2023-07-19
KR20210083287A (ko) 2021-07-06
CN112867715A (zh) 2021-05-28
AU2019363662A1 (en) 2021-03-25
IL282526A (en) 2021-06-30

Similar Documents

Publication Publication Date Title
MX2020010484A (es) Derivados de heterociclilos sustituidos como inhibidores de cdk.
PH12020551305A1 (en) Pharmaceutical Compounds
CY1124631T1 (el) 11-υποκατεστημενες 24-υδροξυστερολες για χρηση στην αγωγη nmda σχετιζομενων παθησεων
GEP20084439B (en) Nitrogen-containing heterocyclic derivatives and pharmaceutical use thereof
MX2019010354A (es) Derivado de heteroaril[4,3-c]pirimidina-5-amina, metodo de preparacion del mismo y usos medicos del mismo.
WO2016142855A3 (en) Pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives as cdk inhibitors
MX2022003102A (es) Degradadores bifuncionales de brd9 y sus metodos de uso.
GEP20217242B (en) Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors
MY167135A (en) Fused heterocyclic derivatives and methods of use
ATE453636T1 (de) Substituierte 2,3-dihydro-1h-isoindol-1-one derivate und anwendungsverfahren
MY177111A (en) Substituted amide derivatives and methods of use
MX2010007683A (es) Derivados heterociclicos fusionados y metodos de uso como inhibidores de c-met.
MX2023005636A (es) Inhibidores de bcl6 derivados de bencimidazolona.
MX2022006086A (es) Derivados de piridopirimidinona como antagonistas de ahr.
MX2021003508A (es) Derivados de 5-azaindazol como antagonistas del receptor de adenosina.
ZA202001295B (en) Thiazolopyridine derivatives as adenosine receptor antagonists
MX2020010568A (es) Derivados de urea ciclica fusionada como antagonista de crhr2.
CR20220160A (es) Derivados de piridazin-3(2h)-ona fusionados con azol
MX2021003901A (es) Derivados de 5-azaindazol como antagonistas del receptor de adenosina.
MX2021008510A (es) Derivados de tiazolopiridina como antagonistas del receptor de adenosina.
ZA202001780B (en) Bezimidazole derivatives as adenosine receptor antagonists
EA202191955A1 (ru) Таблетированные составы с модифицированным высвобождением, содержащие ингибиторы фосфодиэстеразы
MX2021005839A (es) Antagonistas del receptor de adenosina aminotriazolopirimidina y aminotriazolopirazina sustituidos, composiciones farmaceuticas y su uso.
PH12018501285A1 (en) Alkyl dihydroquinoline sulfonamide compounds
PH12018500469A1 (en) Sulfonamide compounds as voltage-gated sodium channel modulators